RRS® HA Long Lasting (1 x 3.0 mL) | Skin Tech Pharma Group (Spain)

Short Description

A hybrid aesthetic injectable and dermal biostimulator formulated with 21 mg / 3 mL (7 mg/mL) of BDDE Cross-Linked Hyaluronic Acid stabilized within an osmoprotective Amino Acid Buffer (14.52 mg / 3 mL). Engineered as a 3-in-1 treatment that Repairs, Refills, and Stimulates, RRS® HA Long Lasting is administered via a standardized 7-Point Vector Injection Technique to counteract photoaging, dermal atrophy, and soft-tissue laxity—delivering immediate hydro-lifting, prolonged matrix hydration, and fibroblast biostimulation with clinical results lasting 9 to 12 months.

Detailed Description

RRS® HA Long Lasting is a sterile, non-pyrogenic, resorbable Class III medical injectable manufactured in Spain by Skin Tech Pharma Group (Aesthetic Dermal). Positioned between traditional non-cross-linked mesotherapy skin boosters and structural dermal fillers, it represents a hybrid biostimulating hydro-lifter designed for comprehensive facial remodeling.

The formulation operates on the “Repair, Refill, Stimulate” principle through two synchronized components:

1. Cross-Linked High-Molecular-Weight Hyaluronic Acid (21 mg / 3 mL): Formulated with resilient BDDE cross-linked sodium hyaluronate with high viscoelastic properties ($G’$). Unlike linear mesotherapy HA that degrades within 48 to 72 hours, this cross-linked lattice resists enzymatic hyaluronidase degradation, establishing a multi-month extracellular hydration scaffold that provides immediate micro-volumetric support, smooths superficial folds, and lifts descending facial vectors.

2. Protective Amino Acid Buffer & Osmolyte Complex (14.52 mg / 3 mL): The cross-linked HA is suspended in an amino acid cluster containing 15 essential and non-essential amino acids (including Glycine, L-Proline, L-Lysine, L-Valine, L-Alanine, L-Leucine, L-Isoleucine, and L-Arginine) alongside stabilizing osmolytes (such as Taurine). This buffer fulfills two clinical roles:

   • Osmotic & Thermal Shielding: Slows the mechanical and oxidative breakdown of the cross-linked HA matrix in vivo, prolonging the gel’s residence time.

   • Direct Fibroblast Substrate Supply: Delivers the biochemical building blocks necessary for dermal fibroblasts to assemble new, triple-helical Type I and Type III collagen fibers and native elastin.

Treatment Areas & Indications

• Full-Face Biorevitalization & Vector Lifting:

  • Chronically dehydrated, dull, or sun-damaged skin (Glogau Phototypes II–IV)

  • Early-to-moderate gravitational soft-tissue sagging and loss of cheek definition

  • Midface tissue deflation and flattening of the malar apex

• Dermal Atrophy & Texture Irregularities:

  • Thinning dermal envelope, loss of skin elasticity, and superficial tissue crepeyness

  • Accordion smile lines and periauricular crinkles

  • Superficial-to-medium facial rhytids and prominent nasolabial creases

• Skin Tone & Complexion Harmonization:

  • Photo-induced epidermal dyschromia, sallow skin tones, and environmental elastosis

• Target Patient Profile: Individuals aged 25 to 55+ seeking natural lifting and lasting skin redensification without the volumetric heaviness of classic dermal fillers.

Key Clinical Advantages

• Generous 3.0 mL Pre-Filled Syringe: Provides enough product in a single syringe to treat the entire face (1.5 mL per side), eliminating the cost and inconvenience of combining multiple 1.0 mL units.

• Hybrid Technology (Filler Lift + Booster Glow): Delivers the instant mechanical smoothing of a light cross-linked filler with the cellular biorevitalization of an amino acid booster.

• Minimally Invasive 7-Point Technique: Uses only 7 strategic micro-bolus entry points per facial side, minimizing procedural trauma, pain, and downtime.

• Controlled BDDE Cross-Linking: Provides stability against thermal and enzymatic breakdown while maintaining low BDDE residue levels, reducing the risk of late-onset nodules or sterile inflammation.

• Extended Clinical Longevity: While linear HA skin boosters require monthly sessions, RRS HA Long Lasting maintains structural hydration and tension for up to 12 months with only 1 to 3 treatments per year.

Clinical Injection Protocol: The 7-Point Facial Technique

RRS® HA Long Lasting is optimized for administration using the standardized 7-Point Tension Vector Technique (or retrograde fanning via microcannula):

Injection Point	Anatomical Landmark	Injection Plane	Delivered Volume	Clinical Action
Point 1	Zygomatic Arch / Malar Prominence	Deep dermis / Subdermal	~0.2 mL	Elevates the lateral cheek apex; vectors upper midface
Point 2	Submalar / Zygomatic Cutaneous Ligament	Deep dermis / Subdermal	~0.2 mL	Re-anchors middle retaining ligaments; supports cheek pad
Point 3	Nasolabial Fold (Superior Angle)	Deep reticular dermis	~0.2 mL	Softens the nasolabial fold; restores deep midface hydration
Point 4	Canine Fossa / Modiolus Lateral Margin	Deep reticular dermis	~0.2 mL	Supports perioral micro-vectors; prevents commissure descent
Point 5	Marionette Line / Mandibular Border	Deep dermis / Subdermal	~0.2 mL	Softens labiomental shadow; reinforces lower facial framework
Point 6	Pre-Jowl Sulcus	Deep subdermal plane	~0.2 mL	Smooths the mandibular margin; blends the pre-jowl divot
Point 7	Mandibular Angle (Gonion)	Subdermal / Supraperiosteal	~0.3 mL	Defines the lower jawline border; pulls lateral facial tension

• Total Volume Per Session: 1.5 mL per facial side (3.0 mL total syringe).

• Cannula Alternative: 25G or 27G (50 mm) blunt microcannula via a single zygomatic insertion point, fanning product throughout the midface and lower jaw vectors.

• Recommended Treatment Schedule: 1 to 3 sessions per year (individualized based on patient age and degree of baseline elastosis).

Technical Specifications

Parameter	Specification
Product Classification	Cross-Linked Hybrid Dermal Biostimulator / CE Class III Medical Device
Manufacturer / Origin	Skin Tech Pharma Group / Aesthetic Dermal (Girona, Spain)
CE Certification	CE Mark 2195 (Class III Injectable Implant)
Cross-Linked Hyaluronic Acid	21 mg per 3 mL syringe (7 mg/mL, BDDE cross-linked)
Protective Amino Acid Buffer	14.52 mg per 3 mL syringe (15 Amino Acids + Osmolytes)
Lidocaine Content	Lidocaine-free
Packaging Presentation	1 x 3.0 mL pre-filled sterile glass syringe
Recommended Needle / Cannula	27G to 30G (13 mm) needles or 25G / 27G (50 mm) blunt microcannulas
Target Injection Planes	Deep reticular dermis, subdermal junction, or supra-fascial plane
Papule Resolution Time	Minor post-bolus papules flatten within 12 to 24 hours post-massage
Expected Clinical Duration	9 to 12 months
Storage Instructions	Store between 2°C and 30°C (36°F to 86°F); protect from sunlight and freezing
Regulatory Category	Prescription Only (Rx) / Professional In-Clinic Use

Comparative Benchmark: Hybrid Biostimulators vs. Traditional Boosters

Feature	RRS® HA Long Lasting	PROFHILO® (Classic)	Restylane® Skinboosters (Vital)	JALUPRO® Super Hydro
HA Technology	BDDE Cross-Linked HA (21 mg/3 mL)	Thermally Cross-Linked (NAHYCO)	BDDE Cross-Linked (NASHA 20 mg/mL)	Linear Non-Cross-Linked Hybrid HA
Secondary Bio-Actives	Amino Acid Buffer (14.52 mg)	None (Pure HA)	None (Pure HA)	7 Amino Acids + 3 Biomimetic Peptides
Volume Per Syringe	3.0 mL	2.0 mL	1.0 mL	2.5 mL
Injection Method	7-Point Vector Technique	5-Point BAP Technique	Multiple micro-papules / Cannula	6+1 BAP Ligament Technique
Mechanical Lift ($G’$)	Moderate-to-High (Soft contour lift)	Low (Fluid spreading)	Low-to-Moderate (Hydro-reserve)	Moderate (Ligament support)
Treatment Frequency	1–3 sessions per year	2 sessions (1 month apart)	3 sessions (2–4 weeks apart)	2 sessions (1 month apart)
Clinical Longevity	Up to 12 months	6 to 9 months	6 to 9 months	6 to 9 months

Professional Advisory: RRS® HA Long Lasting is a Class III medical device intended strictly for certified aesthetic physicians, dermatologists, and plastic surgeons trained in deep intradermal and subdermal injection techniques. Following injection, gentle manual massage over the treated vector zones is recommended to facilitate smooth tissue integration. Injection into the periorbital ring, glabella, lips, or intravascularly is strictly contraindicated.